RL
76
3
NWS
41
2
PCG
75
5
NSC
60
4
URBN
43
5
FE
41
2
TSN
31
3
STZ
50
5
CTSH
66
3
CCL
51
4
TEL
60
2
ADT
46
5
ALL
53
3
AMZN
52
2
PLD
48
3
MLM
37
2
MNST
47
7
FOXA
37
2
TDC
65
6
COP
60
4
RL
76
3
NWS
41
2
PCG
75
5
NSC
60
4
URBN
43
5
FE
41
2
TSN
31
3
STZ
50
5
CTSH
66
3
CCL
51
4
TEL
60
2
ADT
46
5
ALL
53
3
AMZN
52
2
PLD
48
3
MLM
37
2
MNST
47
7
FOXA
37
2
TDC
65
6
COP
60
4
Financhill
Back

Mersana Therapeutics 10K Form

Sell
46

MRSN
Mersana Therapeutics

Last Price:
2.13
Seasonality Move:
33.27%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2020-08-07 10Q MRSN/Mersana Therapeutics Quarterly
2020-05-08 10Q MRSN/Mersana Therapeutics Quarterly
2020-02-28 10K MRSN/Mersana Therapeutics Annual
2019-11-06 10Q MRSN/Mersana Therapeutics Quarterly
2019-08-08 10Q MRSN/Mersana Therapeutics Quarterly
2019-05-09 10Q MRSN/Mersana Therapeutics Quarterly

Receive MRSN News And Ratings

See the #1 stock for the next 7 days that we like better than MRSN

MRSN Financial Statistics

Sales & Book Value

Annual Sales: $36.86M
Cash Flow: $-21.86M
Price / Cash Flow: 0
Annual Sales: $0.07
Price / Book: 30.86

Profitability

EPS (TTM): -0.87000
Net Income (TTM): $-104.77M
Gross Margin: --
Return on Equity: -243.31%
Return on Assets: -44.49%

Mersana Therapeutics Earnings Forecast

Key Mersana Therapeutics Financial Ratios

  • The Research & Development expenses have been 402.30% of Revenue.
  • The Interest Expense is -2.37% of Operating Income.
  • The Net Earning history of MRSN is -465.80% of Total Revenues.
  • Per Share Earnings over the last 9 years have been positive in 5 years.

Mersana Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: MRSN
CUSIP: 59045L
Website: mersana.com

Debt

Debt-to-Equity Ratio: 3.01
Current Ratio: 2.72
Quick Ratio: 2.64

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

MRSN Technical Analysis vs Fundamental Analysis

Sell
46
Mersana Therapeutics (MRSN) is a Sell

Is Mersana Therapeutics a Buy or a Sell?